GILEAD SCIENCES INC.
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000CKGBP2
GILD
GILEAD SCIENCES INC.
GICS: -
·
Sector: -
·
Sub-Sector: -
NAME
GILEAD SCIENCES INC.
ISIN
US3755581036
TICKER
GILD
MIC
XNAS
REUTERS
GILD.OQ
BLOOMBERG
GILD US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Fri, 20.12.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:
J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning at 11:15 a.m. Pacific Time
The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days follo...
Gilead Sciences
Tue, 17.12.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.
...
Gilead Sciences
Tue, 17.12.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241217141411...
Gilead Sciences
Fri, 13.12.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate respons...
Gilead Sciences
Thu, 12.12.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD.
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than ...
Gilead Sciences
Mon, 09.12.2024
Gilead Sciences
US3755581036
Kite, a Gilead Company (Nasdaq: GILD), today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) in patients with relapsed/refractory non-Hodgkin lymphomas (NHL) including follicular lymphoma (FL) or marginal zone lymphoma (MZL). The analysis demonstrated that after a median follo...
Gilead Sciences
Mon, 09.12.2024
Gilead Sciences
US3755581036
Kite, a Gilead Company (Nasdaq: GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucabtagene autoleucel) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) during the 66th Amer...
Gilead Sciences
Sun, 08.12.2024
Gilead Sciences
US3755581036
Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were presented at 66th American Society of Hematology (ASH) Annual Meeting & Exposition.
The...
Gilead Sciences
Tue, 03.12.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203665344/en/
...
Gilead Sciences
Wed, 27.11.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the company’s pivotal Phase 3 PURPOSE 2 trial evaluating twice-yearly lenacapavir for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people.
...
Gilead Sciences
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
